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Werner, Rothmund-Thompson, and Bloom syn-
dromes all present with characteristic cutaneous
findings during childhood and a predisposition for high-
grade osteosarcoma, often at unusual locations, such as
the patella. Although each of these syndromes maps
to a unique genetic locus, the gene products share
significant sequence homology. The latter finding is
intriguing given the clinical similarities between the
syndromes. Osteosarcoma is typically a diagnosis of
childhood among the congenital syndromes. In contrast,
chondrosarcoma presenting as part of an inherited syn-
drome does so late in adult life and is discussed in the
context of specific precursor lesions below.
Sporadic premalignant lesions
Paget’s disease
Both benign and malignant neoplasms arise in the set-
ting of Paget’s disease. The incidence of sarcoma has
been estimated at approximately 1%.2–5 Osteosarcoma
is by far the most common, and fibrosarcoma and chon-
drosarcoma are rarely observed.3–4 At the Mayo Clinic,
73 sarcomas arising in bone affected by Paget’s disease
have been recorded. Osteosarcoma typically affects pa-
tients with polyostotic Paget’s disease, with the pelvis,
femur, humerus, and tibia most often affected.3,6–8 With
the exception of the spine, the location of the sarcomas
parallels the distribution of Paget’s disease. Osteosar-
coma associated with Paget’s disease occurs at a later
age than sporadic osteosarcoma, reportedly affecting
subjects during the sixth to seventh decades.4,9 The
prognosis of sarcoma in a patient with Paget’s disease is
considerably worse than for similar primary tumors,2,3,10
with the 5-year survival as low as 8%. The discrepancy
is multifactorial, related to the age of the patients, inop-
erative sites, fracture, and delay in diagnosis because
the underlying Paget’s disease can mask the clinical and
radiographic findings.
Introduction
The etiology of most malignant bone tumors is poorly
understood, and most bone malignancies are believed
to arise de novo. Nevertheless, a small number of malig-
nant bone tumors arise in recognizable benign precur-
sors, and these lesions may be may be divided into three
conceptual categories: diseases with documented pre-
disposition to malignant bone tumors; sporadic benign
tumors with a known risk for secondary malignancy;
and postradiation malignant tumors (Table 1). The
following review attempts to summarize the more
common entities in each category with an emphasis on
clinical manifestations and pathological findings.
Congenital syndromes associated with bone tumors
A number of inherited conditions have been identified
that predispose the affected individual to malignant
bone tumors, typically osteosarcoma (Table 2). In
general, inherited susceptibility accounts for a small
number of sarcomas in most series. For example, at the
Mayo Clinic, we identified only two examples each of
osteosarcoma arising in the context of familial retino-
blastoma, Rothmund-Thompson syndrome, and Bloom
syndrome (2/1952, 0.1%). Although rare, the molecular
mechanisms of the inherited syndromes may parallel
the mechanisms of the more common sporadic osteo-
sarcomas. Although a complete review of the genetic
mechanisms for all of these syndromes is beyond the
scope of this article, a few unifying points are discussed.
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Radiographically, the sarcomas present (in decreas-
ing frequency) as lytic, mixed, or sclerotic lesions (Fig.
1A)3 in the setting of the coarsened bone (Fig. 1B)
affected by Paget’s disease. Histologically, the tumors
are high-grade osteosarcomas, with striking nuclear
pleomorphism or bizarre giant cells (Fig. 1C,D).
Therapy consists of combined surgical eradication
and chemotherapy and occasionally irradiation. The
term “Paget’s sarcoma” has been used to highlight
the clinical behavior of sarcomas arising in this setting
and potentially to designate patients for specific clinical
trials.
Giant cell tumor
Giant cell tumor (GCT) is a perplexing entity in that it
can demonstrate multiple features of malignancy (high
mitotic rate, necrosis, high cellularity, vascular inva-
sion) and behave in a relatively benign fashion. The
concept of malignant giant cell tumor is further con-
fused by the presence of cytologically benign metastases
that may regress spontaneously. True malignancy in
GCTs can be divided into primary and secondary
types.11–14 Of the 39 malignancies arising from a GCT in
the Mayo Clinic files, 5 (13%) were primary, 26 (67%)
had received radiation, and 8 (21%) were secondary
but without prior irradiation. Secondary malignancy is
more common, and most cases occur after radiotherapy
with an interval of a decade or more.
The most frequent histologic types of secondary ma-
lignancy are osteosarcoma and fibrosarcoma. As such,
the secondary sarcomas are high-grade sarcomas, and
the diagnosis can usually be made with adequate clinical
correlation. Primary malignant GCT can be defined
by the presence of areas of typical GCT adjacent to a
high-grade spindle cell sarcoma. It usually presents in a
slightly older age group than conventional GCT. Impor-
tantly, the radiographic distinction from conventional T
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Table 1. Premalignant conditions of bone
Genetic predisposition
Retinoblastoma
Rothmund Thompson syndrome
Bloom syndrome
Li-Fraumeni syndrome
Sporadic premalignant lesions
Paget’s disease
Giant cell tumor
Chronic osteomyelitis, sinus tract
Osteoblastoma
Chondroid neoplasms
Osteochondroma
Synovial chondromatosis
Enchondroma
Fibrous dysplasia
Postradiation sarcoma
414 A. Horvai and K.K. Unni: Premalignant conditions of bone
Fig. 1A–D. Osteosarcoma arising in Paget’s disease. A Left
ileum with expansile mass in a patient with Paget’s disease. B
Area of Paget’s disease uninvolved by sarcoma. C, D Osteo-
GCT may be subtle. Histologically, the transition be-
tween GCT areas and sarcoma is gradual rather than
abrupt, but the malignant component displays marked
nuclear atypia in most cases. The difficulty in diagnosis
occurs only when the lesion is inadequately sampled or
the malignant component is overlooked when the initial
impression is conventional GCT. That the malignant
component of many so-called primary malignant GCTs
is osteosarcoma blurs the distinction between this entity
and giant-cell-rich osteosarcoma. In any event, the pres-
ence of abnormal osteoid matrix in an otherwise unre-
markable GCT should prompt careful examination of
the mononuclear population for atypia and embedding
additional material if available.
genic sarcoma corresponding to iliac lesion with abundant
hyperchromatic, pleomorphic cells and lace-like osteoid
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Chronic osteomyelitis
Although a well-recognized entity given the relative
frequency of chronic osteomyelitis compared to most
bone tumors, the rate of malignancy in draining sinuses
is estimated to be only 0.5%.15 We have identified 56
cases in Mayo Clinic files. The interval to the develop-
ment of malignancy is highly variable, from as little as 1
year to decades. The clinical clues that suggest malig-
nant transformation include a growing mass, increased
pain, bleeding, or a purulent discharge in a long-
standing sinus.16 Radiographically, an acceleration in
the destructive nature of the lesion and a soft tissue
mass (Fig. 2A) are the rule, although malignant change
Fig. 2A–C. Squamous cell carcinoma arising in chronic osteo-
myelitis with a fistula tract. A Large, destructive lesion of the
femur underneath a fistula tract noted on T1-weighted mag-
netic resonance imaging. B, C Squamous cell carcinoma shows
diagnostic foci of keratinization and intercytoplasmic bridges
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may not demonstrate a significant increase in bone de-
struction in some cases.17,18 Histologically, most cases
are well-differentiated squamous cell carcinoma,17,19 al-
though osteosarcoma,16,20 fibrosarcoma,21 and undiffer-
entiated sarcoma22 have been reported. Squamous cell
carcinoma does not appear to complicate chronic osteo-
myelitis absent a draining sinus. The presence of squa-
mous cells invading bone is diagnostic (Fig. 2B, 2C). In
the series by McGrory et al., the 5- and 10-year survival
for squamous cell carcinomas (69% and 63%, respec-
tively) were not significantly different from those of
age-matched controls, although aggressive surgical
management (amputation) was the rule.19 Despite lim-
ited data for clinical significance, the presence of lymph
node metastasis appears to correlate with a worse
outcome.16,23
Osteoblastoma
Osteoblastoma is, by definition, a benign bone tumor
with a recurrence potential as high as 22%.24 How-
ever, malignant transformation has been reported in
rare cases.25–27 All cases of malignantly transformed
osteoblastomas reported to date have shown a conver-
sion to osteosarcomas only in recurrent tumors. In the
Mayo Clinic files, only one case of malignant transfor-
mation from 108 cases of osteoblastoma has been
recorded. However, the diagnosis of “malignancy” in a
osteoblastoma, recurrent or otherwise, is particularly
difficult because of the aggressive behavior of some
osteoblastomas. Radiographic findings of cortical de-
struction (39%) or suggestive of malignancy (12%) are
not uncommon.24 Furthermore, histologic findings do
not necessarily correlate with aggressive behavior even
in “benign” osteoblastomas.24 Rather, the clinical out-
come correlates with the location such that tumors in
short or flat bones or bones of the neuraxis demonstrate
more aggressive behavior.24,28 The entity “aggressive
osteoblastoma” was introduced by Dorfman and
Weiss29 and Lucas et al.24 to describe lesions with fea-
tures borderline between osteoblastoma and osteo-
sarcoma. A permeative pattern of growth within
intratrabecular spaces and lack of maturation toward
the periphery of the lesion have been described as a
histologic clue for distinguishing osteoblastoma from
osteosarcoma.24,30 However, multifocal tumor growth,
frequently present in osteoblastomas, may be confused
with permeation.31 To complicate matters further, al-
though the mortality associated with osteoblastoma-like
osteosarcoma can be significant from local disease (40%
in one series), the metastatic rate of osteoblastoma-like
osteosarcoma may be low (9%).32 In contrast, the con-
ventional osteosarcoma is considered a systemic disease
at the time of diagnosis. Therefore, we believe a spec-
trum of tumors exists, with osteoblastoma at one end
and osteoblastoma-like osteosarcoma at the other, all
of which are treated with either local or wide excision
depending on the degree of clinical aggressiveness.
Limited molecular data support a possible progression
model in this disease.25,33,34 True transformation to
malignancy, as evidenced by distant metastases, is
extremely rare but should be considered a separate
clinicopathologic entity from osteoblastoma-like
osteosarcoma.25 Osteoblastomas with conversion to
osteosarcoma require aggressive surgical management
combined with chemotherapy similar to conventional
osteosarcomas.
Osteochondroma
The neoplastic nature of the osteochondroma has only
recently come to light with the discovery of loss of het-
erozygosity at the EXT1 locus as well as other clonal
abnormalities35,36 in a subset of these tumors. Osteo-
chondroma is the most common precursor lesion for
secondary chondrosarcoma. At the Mayo Clinic, 127 of
157 (81%) secondary chondrosarcomas arose at the site
of an osteochondroma. Approximately two-thirds of
them were from patients with the sporadic form and
the remainder from patients with multiple osteochon-
dromas. However, the rate of malignant transformation
is thought to be only 1%–8% in sporadic osteochondro-
mas.15,37–39 The incidence of chondrosarcoma arising
in patients with multiple osteochondromas has been
estimated at 5%–35%.37,38,40 The incidence is difficult
to estimate and may be lower, as many solitary osteo-
chondromas may go undiagnosed. Furthermore, these
data are generated from large referral centers and may
overestimate the true incidence secondary to selection
bias.
The average age of the secondary chondrosarcoma
patient is 35 years, younger than patients with primary
tumors.41 Most of these tumors affect the pelvic bones.
The increased thickness of the cartilage cap (normally
1–3 mm) has long been reported as an indicator of po-
tential malignancy. However, it should be noted that in
skeletally immature individuals, a cartilage cap of up to
2cm might be identified. In addition to a thick cartilage
cap, findings that should raise suspicion of malignant
transformation are recent growth of an exostosis in an
adult (Fig. 3A), proximal skeletal location, irregular
mineralization (Fig. 3B), soft tissue invasion, a grossly
irregular surface, or cystic change. Permeation of
trabecular bone is not typically seen with chondrosarco-
mas arising in osteochondromas. Cytologically, most
secondary chondrosarcomas are of low grade, although
the normal columnar arrangement of chondrocytes is
lost (Fig. 3C,D). Secondary chondrosarcomas arising in
osteochondromas generally carry a good prognosis, and
surgical treatment without adjuvant chemotherapy or
Fig. 3A–D. Chondrosarcoma arising in an osteochondroma.
A Large, ill-defined soft tissue mass with ring-like calci-
fications arising at the site of prior osteochondroma in the
humerus. B Gross pathology of chondrosarcoma arising from
osteochondroma of the sacrum demonstrates irregular miner-
alization and cystic degeneration. C Loss of columnar archi-
tecture and thick cartilage cap (edge of cap is visible at top
right) are common. D In a grade I chondrosarcoma cytology is
typically bland
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irradiation is the rule. Case reports of osteosarcoma
arising within an osteochondroma have been pub-
lished,42–44 but this event is extremely rare.
Enchondroma
Controversy exists in the literature about the develop-
ment of secondary chondrosarcoma from enchon-
droma. In the Mayo Clinic series of 157 secondary
chondrosarcomas, none had a documented history of a
precursor solitary enchondroma. It is important to note
that even benign enchondromas of the small bones of
the hands and feet may show histological features of
malignancy (hypercellularity, myxoid change, nuclear
hyperchromasia) but nevertheless behave in a benign
fashion. Indeed, an unequivocal diagnosis of malig-
nancy at these sites requires extensive destructive
or permeative soft tissue growth or evidence of
metastasis.45,46
Multiple enchondromas
Patients with multiple enchondromas (enchondro-
matosis) in the setting of Ollier’s disease or Mafucci’s
syndrome carry a significantly higher risk of transforma-
tion to secondary chondrosarcoma than those with soli-
tary enchondromas discussed above. Of 158 secondary
chondrosarcomas seen at the Mayo Clinic, 21 (13%)
had preexisting enchondromatosis.
The genetic mechanisms of these diseases are poorly
understood but may involve mutations in the para-
thyroid hormone receptor 1 (PTHR1) gene in some
cases,47,48 although the diseases are not heritable.
Ollier’s disease usually presents with multiple enchon-
dromas of varying size affecting any bones undergoing
endochondral ossification but with a predilection for the
femur and tibia. Although involvement may be unilat-
eral, it is often bilateral in the hands and feet (Fig. 4A).
The rate of chondrosarcoma in Ollier’s disease has been
estimated at 30%–50%.49,50 Given the hypercellularity
of enchondromas in Ollier’s disease, the histological
distinction may be difficult. However, radiographic evi-
dence of cortical destruction and soft tissue extension
(Fig. 4B) and the histological findings of abundant
myxoid change, cyst formation, and permeation of
existing trabeculae (Fig. 4C) suggest malignancy.
Mafucci’s syndrome demonstrates multiple chondroid
masses similar to Ollier’s disease in addition to soft
tissue hemangiomas. The risk of chondrosarcoma is
approximately 15%–35%.51,52 The appearance of the
chondromas and the criteria for chondrosarcoma in
Mafucci’s syndrome are similar to those for Ollier’s
disease.
Synovial chondromatosis
Secondary malignancy in synovial chondromatosis
has been reported53,54 but is exceedingly rare.
Synovial chondrosarcoma, without prior evidence of
chondromatosis, was first described by Goldman and
Lichtenstein.55 In the Mayo Clinic series, only 3 of 158
(2%) of secondary chondrosarcomas arose in synovial
chondromatosis.37 Synovial chondromatosis has mor-
phological and clinical overlap with soft tissue chon-
droma and is distinct from cartilaginous loose bodies
(so-called secondary synovial chondrometaplasia).56,57
Specifically, the cartilage grows in lobules of solid ma-
trix, with chondrocytes arranged in clusters (Fig. 5A,B).
The soft tissue location, its locally aggressive nature,
and common histological findings of clustering, hyper-
cellularity, and frequent nuclear hyperchromasia or
binucleation may lead to overdiagnosis of chondrosar-
coma. A true diagnosis of chondrosarcoma requires the
presence of a sheet-like growth pattern, loss of cluster-
ing of chondrocytes, or spindling at the periphery of
lobules (Fig. 5C,D).58
Fibrous dysplasia
Fibrous dysplasia is a relatively common lesion, and
therefore fairly large series have reviewed its premalig-
nant potential. Malignant transformation in fibrous
dysplasia, most commonly to osteosarcoma, has been
documented15,59,60,61 at a rate of 0.4%–2.0%. However,
approximately half of the patients in the Mayo Clinic
series also had a history of irradiation.60 The risk of
osteosarcoma appears to be somewhat higher in polyos-
totic fibrous dysplasia,16,61 although it is unclear whether
patients with the McCune-Albright or Mazabraud syn-
dromes are still at further increased risk. Fibrosarcoma
and “malignant fibrous histiocytoma” have been associ-
ated with fibrous dysplasia but not specifically with the
McCune-Albright or Mazabraud syndrome.
The most common sites of malignant transformation
tend to parallel the common sites of fibrous dysplasia:
craniofacial bones, proximal femur, humerus, and pelvis
(in order of decreasing incidence).62 Typically, fibrous
dysplasia represents a benign developmental abnormal-
ity in which the medulla is replaced by immature fibrous
tissue and distorted trabeculae of primitive bone. The
radiographic and histological features of secondary
osteosarcomas are usually high grade and carry a poor
prognosis. The histological findings of benign fibrous
dysplasia may raise the differential diagnosis of low-
grade central osteosarcoma,63,64 although these entities
are likely unrelated. Degenerative nuclear changes
mimicking atypia may be seen with fibrous dsyplasia,65
but fibrous dysplasia should not demonstrate an infil-
trating pattern along the peripheral native bone, even if
radiographic features suggest a benign lesion.
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Fig. 4A–C. Chondrosarcoma arising in the setting of multiple
enchondromas. A Plain radiograph from an Ollier disease
patient demonstrating multiple enchondromas of the digits. B
Computed tomography scan from an Ollier disease patient
showing a large, destructive mass of the ileum. C Permeation
of existing trabecular bone is diagnostic of chondrosarcoma
Postradiation sarcoma
The first description of sarcoma arising in irradiated
bone was recorded by Cahan et al.,66 and sarcoma is now
a well-studied, albeit rare, detrimental effect of ionizing
radiation. The term postradiation sarcoma is preferred
to radiation-induced sarcoma. To be classified as a
postradiation sarcoma requires at least three condi-
tions: (1) the bone must have been included in the radia-
tion field; (2) a latency period; and (3) histological
confirmation of sarcoma.16 Histological confirmation is
of particular import to confirm that the sarcoma differs
from the original lesion. The incidence of postradiation
sarcoma is not known, in part, because early studies
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reported the effects of irradiation for benign pro-
cesses,66–72 whereas more recent work has focused
on irradiation of malignancies, particularly breast can-
cer.73–78 The overall incidence in adults ranges from
0.1% to 0.78%,67,79 although these figures include soft
tissue as well as bone sarcomas. In children, particularly
those treated for Ewing’s sarcoma, the rate has been
Fig. 5A–C. Chondrosarcoma in synovial chondromatosis.
A The benign cartilage of synovial chondromatosis shows
a lobular growth pattern at low power. B Synovial
chondromatosis often demonstrates chondrocyte clustering,
nuclear hyperchromasia, and binucleation and should not be
mistaken for chondrosarcoma. C Plain radiograph of a patient
with synovial chondromatosis and knee hemiarthroplasty with
a new ill-defined soft tissue density adjacent to the knee joint.
D Loss of clustering and spindling of chondrocytes at the
periphery of a lobule are suggestive of chondrosarcoma in this
setting
reported to be as high as 22% if followed more than 20
years,80 although rates as low as 1% have also been
reported.81–83
In the Mayo Clinic series of postradiation sarcoma,
the most common indication for the irradiation was a
benign bone lesion (giant cell tumor or fibrous dyspla-
sia).84 Although there is no absolute minimum interval
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between irradiation and the sarcoma, most cases
present at least 4 years after irradiation (mean 13
years).67,85,86 The most common interval was 5–9 years
(33.5% of cases) in the Mayo Clinic series,84 and the
most common postirradiation sarcoma was osteosar-
coma (62%). However, irradiation of breast carinoma
tends to produce sarcomas of soft tissues (most com-
monly angiosarcoma) rather than of bone.87 Thus, given
the unfortunately high incidence of breast carcinoma
requiring radiation therapy, and the decrease in the use
of irradiation for benign bone lesions, the incidence of
postradiation bone sarcomas may decrease. In general,
the prognosis of postradiation sarcoma of bone has
been regarded as very poor, with the 5-year survival
ranging from 9% to 29%.67,85,88–90 However, in the Mayo
Clinic series, those with operable extremity sarcomas
showed a 5-year survival of 68%.84 Unfortunately, this
group represented only 23% of the patients, and par-
ticularly unfavorable outcomes were associated with
tumors of the pelvis, spine, shoulder girdle, and skull.
Central lesions may predict a worse prognosis because
of delay in diagnosis and unresectability. Often the only
clinical clue to the development of a postradiation sar-
coma is bone pain, which may be a relatively nonspecific
symptom in patients with cancer. Radiographically, the
presence of cortical bone destruction or a mineralized
soft tissue mass in an irradiated field should prompt
needle biopsy of the lesion.84 Patients with postradiation
sarcoma of the extremity should undergo aggressive
wide resection if possible.
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